manilatimes

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using ...
technologynetworks

Seer To Feature Proteomic Advancements in Cancer and RNA Therapy Research Among Other Findings at US HUPO 2025

Seer, Inc. (Nasdaq: SEER), announced that the company will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025. As ...
The Globe and Mail

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the ...
Nasdaq

Seer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE Assay

Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...
Seeking Alpha

Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER) (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced ...
GEN

Seer Showcases Deep Proteomics Capabilities, Announces Co-Marketing Deal with Thermo Fisher Scientific

At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...